Samenvatting
BACKGROUND: Transcranial direct current stimulation (tDCS) is used to modulate neuronal activity, but the exact mechanism of action (MOA) is unclear. This study investigates tDCS-induced modulation of the corticospinal excitability and the underlying MOA. By anesthetizing the scalp before applying tDCS and by stimulating the cheeks, we investigated whether stimulation of peripheral and/or cranial nerves contributes to the effects of tDCS on corticospinal excitability.
MATERIALS AND METHODS: In a randomized cross-over study, four experimental conditions with anodal direct current stimulation were compared in 19 healthy volunteers: 1) tDCS over the motor cortex (tDCS-MI), 2) tDCS over the motor cortex with a locally applied topical anesthetic (TA) on the scalp (tDCS-MI + TA), 3) DCS over the cheek region (DCS-C), and 4) sham tDCS over the motor cortex(sham). tDCS was applied for 20 minutes at 1 mA. Motor evoked potentials (MEPs) were measured before tDCS and immediately, 15, 30, 45, and 60 minutes after tDCS. A questionnaire was used to assess the tolerability of tDCS.
RESULTS: A significant MEP amplitude increase compared with baseline was found 30 minutes after tDCS-MI, an effect still observed 60 minutes later; no time∗condition interaction effect was detected. In the other three conditions (tDCS-MI + TA, DCS-C, sham), no significant MEP modulation was found. The questionnaire indicated that side effects are significantly lower when the local anesthetic was applied before stimulation than in the other three conditions.
CONCLUSIONS: The significant MEP amplitude increase observed from 30 minutes on after tDCS-MI supports the modulatory effect of tDCS on corticospinal neurotransmission. This effect lasted one hour after stimulation. The absence of a significant modulation when a local anesthetic was applied suggests that effects of tDCS are not solely established through direct cortical stimulation but that stimulation of peripheral and/or cranial nerves also might contribute to tDCS-induced modulation.
Originele taal-2 | Engels |
---|---|
Tijdschrift | Neuromodulation |
Volume | XX |
Nummer van het tijdschrift | X |
Vroegere onlinedatum | 14 jun. 2024 |
Status | E-publicatie vóór gedrukte publicatie - 14 jun. 2024 |
Bibliografische nota
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.Financiering
Source(s) of financial support: Evelien Carrette is supported by a research grant from the Geneeskundige Stichting Koningin Elisabeth. Robrecht Raedt is supported by grants of the FWO (Fonds Wetenschappelijk Onderzoek) Flanders and Bijzonder Onderzoeks Fonds (BOF)\u2013UGent special research fund. Kristl Vonck has been funded by the BOF-UGent special research fund. Paul Boon is supported by grants of the FWO Flanders, BOF-UGent, Ghent University Hospital, and E-Epilepsy (European Union). The study was part of a collaboration project entitled \u201CPerStim,\u201D which is cofunded by the Dutch PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health to EpilepsieNL to stimulate public-private partnerships.Emma Lescrauwaet, Ann Mertens, Chlo\u00E9 Algoet, Evelien Carrette, and Robrecht Raedt reported no conflict of interest. Debby Klooster was supported by a FWO junior postdoctoral grant (1259121N). Mathieu Sprengers, Steven Beumer, and Rob Mestrom were partially funded by the Dutch PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, to EpilepsieNL. Kristl Vonck obtained a Bijzonder Onderzoeks Fonds (BOF) grant of Ghent University for the purchase of transcranial magnetic stimulation (TMS) equipment, obtained consultancy fees from LivaNova, Synergia Medical, All Man Foundation, Precisis, and Angelini Pharma and participates in the advisory board of LivaNova, Synergia Medical, Precisis, and Angelini Pharma. Paul Boon obtained a BOF grant of Ghent University for the purchase of TMS equipment, obtained consultancy fees from LivaNova, Medtronic, and Angelini Pharma and participates in the advisory board of LivaNova, Synergia Medical, and Medtronic.
Financiers | Financiernummer |
---|---|
Angelini Pharma | |
Fonds Wetenschappelijk Onderzoek | |
European Commission | |
Ghent University Hospital | |
Medtronic, Inc. | |
Health~Holland | 1259121N |